To evaluate the translational value of this triple combination therapy in an autoimmune model of diabetes, we used Repsox and the γ-secretase inhibitor PF-03084014, currently in phase II trials for the treatment of different forms of cancer (36), in combination with the chemical FOXO1 inhibitor FBT10 (Figure 6A) (20, 21). The gene discussed is FOXO1; the disease is diabetes mellitus.